Meeting
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).
Authors
Mrinal M. Gounder
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Mrinal M. Gounder , Silvia Stacchiotti , Patrick Schöffski , Steven Attia , Antoine Italiano , Robin Jones , George D. Demetri , Stephen Blakemore , Alicia Clawson , Scott Daigle , Scott Ribich , Maria Roche , Jill Rodstrom , Peter T.C. Ho , Gregory Michael Cote
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02601950
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11058)
DOI
10.1200/JCO.2017.35.15_suppl.11058
Abstract #
11058
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
First Author: Zhengfu Fan
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.
First Author: Shiraj Sen
Poster
2018 ASCO Annual Meeting
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
First Author: Marjorie Glass Zauderer
Poster
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).
First Author: Patrick Schoffski